Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics for serious viral diseases, and its news flow reflects this development-driven profile. Company announcements frequently center on progress in its hepatitis C virus (HCV) program, where Atea is advancing a fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and ruzasvir, an NS5A inhibitor.
News items include updates on the global Phase 3 HCV program, such as enrollment milestones in the C-BEYOND and C-FORWARD trials, expectations for topline results, and details of trial design, endpoints and patient populations. Atea also reports new clinical and nonclinical data, including Phase 2 efficacy results, resistance analyses, pharmacokinetic findings and multiscale modeling that explore the regimen’s antiviral activity, barrier to resistance, relative bioavailability and dosing flexibility.
Investors and observers can also find press releases about Atea’s participation in major medical and investor conferences, including presentations at The Liver Meeting of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Congress, as well as appearances at healthcare investment conferences. These communications often highlight new data sets, key opinion leader events and discussions of the HCV commercial landscape.
In addition, Atea’s news coverage includes pipeline expansion updates, notably the development of nucleotide analog candidates AT-587 and AT-2490 for hepatitis E virus (HEV), along with background on the unmet medical need in HEV and the company’s preclinical findings. Financial results releases and business updates, furnished in connection with quarterly reports, provide further context on research and development spending, cash resources and strategic priorities. For those tracking AVIR, this news page offers a centralized view of clinical progress, scientific presentations, pipeline evolution and corporate developments.
Atea Pharmaceuticals (NASDAQ: AVIR) announced positive Phase 2 study results for its HCV treatment combining bemnifosbuvir and ruzasvir. The study met its primary endpoints with a 98% sustained virologic response rate at 12 weeks post-treatment in treatment-adherent patients after an eight-week regimen.
The treatment showed 95% efficacy in the overall evaluable population, including non-adherent patients. The regimen was generally safe with no drug-related serious adverse events. Non-cirrhotic patients achieved a 99% success rate, while cirrhotic patients showed 88% efficacy.
The company plans to initiate a Phase 3 program in early 2025, following an FDA meeting. The upcoming phase will feature a fixed-dose combination tablet, reducing daily pill count from four to two tablets.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has announced its participation in the 7th Annual Evercore HealthCONx Conference. Jean-Pierre Sommadossi, CEO and Founder, along with the management team, will deliver a business update and participate in a fireside chat on December 4, 2024, at 9:35 a.m. ET. The presentation will be accessible via live webcast on the company's website and will remain available for at least 90 days after the event.
Atea Pharmaceuticals (AVIR) presented three posters at AASLD's The Liver Meeting 2024 supporting the combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) treatment. The Phase 2 lead-in cohort showed a 97% SVR12 success rate with an 8-week treatment course. Key findings include: the drug combination effectively blocks viral replication and assembly, bemnifosbuvir demonstrates no clinically relevant effects on cardiac function, and shows a high barrier to resistance. The company plans to report full Phase 2 results in early December and initiate Phase 3 development in early 2025.
Atea Pharmaceuticals (AVIR) reported Q3 2024 financial results and provided updates on its HCV program. The company expects topline SVR12 results from its global Phase 2 Hepatitis C study (N=275) in December 2024. Earlier data showed 97% SVR12 rate in efficacy evaluable patients. The company ended Q3 with $482.8 million in cash and equivalents. Research and development expenses were $26.2 million, down from $28.2 million year-over-year. The company reported a net loss of $31.2 million for Q3 2024. Notably, Atea announced it will not pursue COVID-19 treatment development after its Phase 3 SUNRISE-3 trial failed to meet its primary endpoint.
Atea Pharmaceuticals (Nasdaq: AVIR) announced it will host a conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to discuss third quarter 2024 financial results and provide a business update. The event will be accessible via telephone registration and webcast through the company's investor relations website. An archive of the webcast will be available for at least 90 days following the event.
Atea Pharmaceuticals (NASDAQ: AVIR) announced three upcoming poster presentations at AASLD's The Liver Meeting 2024 in San Diego, showcasing new data on the combination of bemnifosbuvir and ruzasvir for Hepatitis C Virus (HCV) treatment. The combination, currently in Phase 2 development, pairs a nucleotide analog polymerase inhibitor with an NS5A inhibitor.
The presentations, scheduled for November 15, will cover multiscale modeling of Phase 2 study results, cardiac repolarization effects, and resistance barrier studies. The company aims to address unmet needs in HCV treatment, particularly for patients with substance abuse disorders and comorbidities, and plans to advance to Phase 3 development following Phase 2 results later this year.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that its global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19 treatment did not meet its primary endpoint. The trial, involving 2,221 high-risk patients with mild to moderate COVID-19, failed to show a statistically significant reduction in all-cause hospitalization or death through Day 29 compared to placebo. Despite the disappointing outcome, bemnifosbuvir was generally safe and well-tolerated.
The company attributed the trial's failure to the evolving nature of COVID-19 variants and the trend towards milder disease, resulting in fewer hospitalizations and deaths. Notably, severe respiratory disease caused by COVID was not observed in SUNRISE-3, unlike in previous studies. Atea will not pursue a regulatory pathway for bemnifosbuvir in COVID-19 treatment but remains focused on developing a combination of bemnifosbuvir and ruzasvir for hepatitis C treatment.
Atea Pharmaceuticals (Nasdaq: AVIR) has published new data in PLOS Biology, detailing the metabolic activation pathway of bemnifosbuvir, their oral antiviral drug candidate. The study elucidates how bemnifosbuvir converts into its active form, AT-9010, which selectively inhibits viral enzymes, leading to potent antiviral activity against COVID-19, HCV, and potentially other RNA viruses.
Key findings include:
- Bemnifosbuvir's activation pathway to AT-9010 halts HCV RNA synthesis through chain termination
- It targets SARS-CoV-2 RNA synthesis at two distinct sites
- The drug shows minimal cellular toxicity compared to other antiviral purine nucleotide analogues
Bemnifosbuvir is currently in Phase 3 trials for COVID-19 and Phase 2 trials for HCV in combination with ruzasvir.
Atea Pharmaceuticals (NASDAQ: AVIR) reported Q2 2024 financial results and provided a business update. Key highlights include:
- Full enrollment achieved in global Phase 2 HCV study; SVR12 results expected Q4 2024
- COVID-19 Phase 3 SUNRISE-3 trial results expected H2 2024
- Cash position of $502.2 million as of June 30, 2024
- Q2 2024 R&D expenses increased to $34.7 million from $22.1 million in Q2 2023
- Net loss of $40.5 million for Q2 2024 compared to $28.2 million in Q2 2023
The company completed enrollment in both the HCV Phase 2 study and COVID-19 Phase 3 SUNRISE-3 study. Positive HCV data presented at EASL showed 97% SVR12 rate in lead-in cohort. Atea selected a fixed-dose combination tablet for HCV Phase 3 program.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics for serious viral diseases, has announced its upcoming second quarter 2024 financial results conference call. The event is scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET.
Participants can join the live audio webcast through the Investor Relations section of Atea's website. For those joining via telephone, pre-registration is required. The company will provide a business update along with the financial results for the quarter ended June 30, 2024. An archive of the webcast will be available on Atea's website for at least 90 days following the event.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
